Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bishop

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferaseAlan B Cooper, Corey L Strickland, James Wang, et al.
Molecular Cancer Therapeutics|February 4, 2010
A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenograftsYaolin Wang, Philip Lipari, Xiaoying Wang, et al.
Anti-Cancer Drugs|August 2, 2007
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)Gonjgie Liu, Cindy H Marrinan, Stacey A Taylor, et al.
Bioorganic & Medicinal Chemistry Letters|January 9, 2010
Discovery of C-imidazole azaheptapyridine FPT inhibitorsHugh Y Zhu, Alan B Cooper, Jagdish Desai, et al.
Oncogene|June 6, 2003
Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progressionAsra Mirza, Qun Wu, Luquan Wang, et al.
The Journal of Biological Chemistry|January 22, 2005
Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional targetQun Wu, Wei Ding, Asra Mirza, et al.
The Journal of Biological Chemistry|February 4, 2010
SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53Mark Demma, Eugene Maxwell, Robert Ramos, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|April 16, 2011
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathiesKatherine A Rauen, Anuradha Banerjee, W Robert Bishop, et al.
Oncogene|April 20, 2002
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathwayAsra Mirza, Marnie McGuirk, Tish N Hockenberry, et al.
Molecular Cancer Therapeutics|August 12, 2005
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibodyYan Wang, Judith Hailey, Denise Williams, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|February 15, 2002
Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferaseAlan B Cooper, Corey L Strickland, James Wang, et al.
Molecular Cancer Therapeutics|February 4, 2010
A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenograftsYaolin Wang, Philip Lipari, Xiaoying Wang, et al.
Anti-Cancer Drugs|August 2, 2007
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)Gonjgie Liu, Cindy H Marrinan, Stacey A Taylor, et al.
Bioorganic & Medicinal Chemistry Letters|January 9, 2010
Discovery of C-imidazole azaheptapyridine FPT inhibitorsHugh Y Zhu, Alan B Cooper, Jagdish Desai, et al.
Oncogene|June 6, 2003
Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progressionAsra Mirza, Qun Wu, Luquan Wang, et al.
The Journal of Biological Chemistry|January 22, 2005
Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional targetQun Wu, Wei Ding, Asra Mirza, et al.
The Journal of Biological Chemistry|February 4, 2010
SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53Mark Demma, Eugene Maxwell, Robert Ramos, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|April 16, 2011
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathiesKatherine A Rauen, Anuradha Banerjee, W Robert Bishop, et al.
Oncogene|April 20, 2002
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathwayAsra Mirza, Marnie McGuirk, Tish N Hockenberry, et al.
Molecular Cancer Therapeutics|August 12, 2005
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibodyYan Wang, Judith Hailey, Denise Williams, et al.
Pageof 6